QT time prolongation
Adverse drug events
|Taste sense altered|
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Explanations of the substances for patients
We have no additional warnings for the combination of rucaparib and abarelix. Please also consult the relevant specialist information.
The reported changes in exposure correspond to the changes in the plasma concentration-time curve [ AUC ]. We do not expect any change in exposure for rucaparib, when combined with abarelix (100%). We do not expect any change in exposure for abarelix, when combined with rucaparib (100%).
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of rucaparib is unknown. Protein binding [ Pb ] is not known. The metabolism takes place via CYP1A2, CYP2D6 and CYP3A4, among others and the active transport takes place partly via BCRP and PGP.
The bioavailability of abarelix is unknown. The terminal half-life [ t12 ] is rather long at 316.8 hours and constant plasma levels [ Css ] are only reached after more than 1267.2 hours. The protein binding [ Pb ] is 97.5% strong. The metabolism via cytochromes is currently still being worked on.
|Serotonergic Effects a||0||Ø||Ø|
Rating: According to our knowledge, neither rucaparib nor abarelix increase serotonergic activity.
|Kiesel & Durán b||0||Ø||Ø|
Rating: According to our knowledge, neither rucaparib nor abarelix increase anticholinergic activity.
QT time prolongation
Rating: In combination, rucaparib and abarelix can potentially trigger ventricular arrhythmias of the torsades de pointes type.
General adverse effects
|Side effects||∑ frequency||ruc||aba|
|Taste sense altered||39.5 %||39.5||n.a.|
|Abdominal pain||39.0 %||39.0||n.a.|
|Loss of appetite||31.0 %||31.0||n.a.|
Dyspnea (21%): rucaparib
Pneumonia (19.9%): rucaparib
Upper respiratory infection: rucaparib
Hypersensitivity reaction (19.9%): rucaparib
Infection (19.9%): rucaparib
Thrombocytopenia (7.5%): rucaparib
Myelodysplastic syndrome: rucaparib
Elevated ALT: rucaparib
Based on your answers and scientific information, we assess the individual risk of undesirable side effects. These recommendations are intended to advise professionals and are not a substitute for consultation with a doctor. In the restricted test version (alpha), the risk of all substances has not yet been conclusively assessed.
No literature information available.